Studying How Climate Disaster Responses Impact Post-NSCLC Surgery Survival

Commentary
Video

Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.

Leticia Nogueira, PhD, MPH, highlighted the next steps for researching response strategies for patients who undergo lung cancer surgery in the event of wildfires and other climate disasters. She spoke in the context of a study she published showing that patients who recovered from lung cancer surgery at facilities exposed to wildfires tended to have longer lengths of stay (LOS) compared with those who recovered at facilities without wildfire exposure.

Looking ahead, Nogueira, scientific director of Health Services Research at the American Cancer Society, stated that future work may focus on determining whether an extended LOS in the event of wildfire exposure may impact survival among patients who receive lung cancer surgery. Other priorities may include identifying optimal strategies for protecting patient health during wildfires and other climate disasters. According to Nogueira, proper response strategies may vary depending on the specific kind of climate disaster as well as a patient’s type of disease.

Findings from Nogueira’s study showed that among all patients in the study, the LOS was 7.45 days (SE, 0.22) for those who received surgery at facilities without wildfire exposure vs 9.42 days (SE, 0.25) among patients who underwent treatment at facilities exposed to wildfires (P <.0001).

Transcript:

The next steps for this specific patient population would be to test if staying in the hospital for a couple of additional days has an impact on survival. Does it make a difference? But similar to other disasters and other patient populations, what are any strategies that we can have to better protect the health and safety of these people during a disaster? Is it staying longer in the hospital? Is it helping the patient, the caregiver, and the support network to create a disaster preparedness plan and evacuation plan? Is it a patient transfer agreement? Is it a recommendation to wear a mask?

We do not know because we have not studied it. The next steps would be to prioritize this type of research and work together to figure out what works and what doesn’t work. It might be different things for different types of disasters. A wildfire might be different than a flood, and different patient populations. Lung cancer vs leukemia might be completely different.

Reference

Nogueira LM, Yabroff KR, Yates E, Shultz JM, Valdez RB, Nori-Sarma A. Facility exposure to wildfire disasters and hospital length of stay following lung cancer surgery. JNCI. Published online March 11, 2025. doi:10.1093/jnci/djaf040

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Related Content